covid-19疫苗研究

karisa Steffans,高科技编辑

随着校园关闭,所有在新闻报道这么多关于正在发生的事情与冠状病毒的传播,大多数人都知道已经是疾病及其症状。已被关停学校,餐馆都关闭了,人被建议避免前往不亚于必要。然而,这些建议都旨在减缓疾病的传播。没有人能够帮助治疗,如果抓住了,很多公司都抢着现在尝试和创建治疗或预防接种对ESTA疾病的一些方法。

There are many companies around the world joining in the efforts to help treat coronavirus. All of them are at various stages within their production, however, progress is being made as quickly as possible. Some companies that are looking into treatment include Gilead Sciences, Johnson & Johnson, Regeneron Pharmaceuticals, and Vir 高科技nology. Those that are looking into vaccines include Moderna Therapeutics, CureVac, GlaxoSmithKline, Inovio Pharmaceuticals, Johnson & Johnson, and Sanofi. These are just some of those looking for answers on what to do about this rapidly spreading disease, and all of them are at various stages of producing results.

CureVac和现代疗法使用的是类似的两种方法来他们正在赶制疫苗。他们的目标是将身体推到制造抗体抵御病毒,利用的信使核糖核酸,通常被称为基因合成产生链。 RNA的ESTA形式就是在身体发出指示创建的蛋白质,这就是为什么插入的这一正确的形式可以有效地带动身体产生抗体根据需要参与其中。 CureVac预计公司而现代疗法在下个月的月初开始他们的ESTA疫苗的版本以志愿者为基础的研究进行了短短几个月内他们的疫苗的人体试验准备。尽管他们的进步,然而,现代的治疗一直在努力获得食品和药物管理局批准,任何基因疫苗。

葛兰素史克公司采取了不同的方法来尝试与人体的免疫系统推入动作与他们的疫苗。相反,利用基因这将推动身体产生的蛋白质,该公司有意在注射到体内蛋白质产生免疫应答。他们还没有指明时,他们想到要准备好他们的疫苗的人体试验,但是。

Contrasting with the majority of the other companies working within the medical field on the coronavirus, Johnson & Johnson is attempting to complete a form of treatment and a vaccine. They have had a history of strong responses to outbreaks of other diseases such as Ebola and the Zika virus a few years ago. Now, they are working on developing a vaccine using one of the more standard approaches to vaccination. The idea behind this form of vaccination is to introduce the body to a deactivated version of a virus. This would allow the body to start an immune response, without actually becoming ill with the infection. For their process of looking into potential treatments, Johnson & Johnson is currently looking into their older medications and attempting to see if they have any effect on lessening the severity of the symptoms caused 通过 the virus.

此外Regeneron公司制药正在努力的方式来治疗病毒,而不是预防接种反对。 Regeneron公司是已知的STI工作,基因改造小鼠,帮助他们创造的人类抗体的公司。 ESTA允许他们采取尝试引入模拟到冠状病毒到这些小鼠的一个有趣的方法。我们的目标是让小鼠产生抗体的人会需要能够应对病毒和更快的打它关闭。 Regeneron公司制药预计将在夏末今年是准备人体试验随着该处理方法。

另一家公司正在努力维尔生物技术处理。这家公司正在从另一种病毒被称为SARS的幸存者分离抗体。 SARS是一样的冠状病毒,和希望是非典的答复中说在身体类似于需要战斗的冠状病毒的响应。他们是在早期阶段目前正在开发他们的治疗,正因为如此,他们也有对如何尽快处理将是他们准备试验范围内的公众不预测。

有被调查,试图帮助更多的人从完全收缩它增加他们的生存ESTA疾病及预防的可能性许多其他方法。需要时间疫苗的研究,而且有很多的方式来创建内体内的免疫反应,正如-进行了描述。在那之前,最好遵循由疾病预防中心给出的建议,并保持自己的通报中正在建立以治疗和预防疾病的ESTA什么进展。